|
1
|
Sciascia S, Radin M, Cecchi I, Di Nunzio P, Buccarano N, Di Gregorio F, Valeria M, Osella S, Crosasso P, Favuzzi MD, Rubini E, Foddai SG, Baldovino S, Roccatello D, Rossi D. Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study. Int J Environ Res Public Health 2020; 17:ijerph17103469. [PMID: 32429245 PMCID: PMC7277549 DOI: 10.3390/ijerph17103469] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 05/11/2020] [Accepted: 05/12/2020] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To create a mobile application able to help patients follow medical treatments properly. METHODS We designed and developed a custom Android/iOS App to remind patients of the pharmaceutical drugs to be taken, of the visits and exams to attend, and to detect their compliance with their personal therapeutic plan. In this paper we describe the App development, UX/UI design, Gamification. TuTOR is an Android and iOS application designed to remind patients of the drugs to be taken, giving them all the information related to their therapeutic plans in a simple and non-invasive way. Thanks to a dedicated back-office, specially designed to meet specific medical information needs, the App can also help physicians detect their patients' compliance with their treatments and modify prescriptions in real time. The App also ensures a state-of-the-art approach to data security and privacy protection. The main feature of TuTOR is the smart therapy assistant, which features dedicated alarms to remind users of taking their prescription drugs. Thanks to the automatic synchronization with a local database, the alert system works even without connection to the Internet. Particular attention was paid during the App's design process: we looked to create an intuitive interface to ensure absolute ease of use, with state-of-the-art visual design aimed at maximizing user experience. Other relevant features include the App's ability to givevisual evidence of the most important drugs to be taken and its note-taking feature, which gives patients the possibility to note down indications on why a specific drug was skipped. The App also keeps track of upcoming medical exams, laboratory tests, and visits on a devoted calendar. It also helps patients by listing therapy contacts, such as physicians' phone numbers, and indicates all medical references by showing, for example, locations of relevant clinics and pharmacies on a map. Thanks to specific visual progress indicators and an innovative gamification approach, the App encourages users to faithfully follow therapy guidelines. With TuTOR, assessing the therapy's state of completion is quick and easy.Thanksto the privacy-by-design approach used, all data managed by the system is compliant with the European Privacy Regulation and it is not available to third parties. EXPECTED RESULTS A mobile App for medication adherence might increase objectively and subjectively measured adherence.
Collapse
Affiliation(s)
- Savino Sciascia
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
- Correspondence: ; Tel.: +39-0112402056; Fax: +39-0112402052
| | - Massimo Radin
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Irene Cecchi
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | | | | | | | - Milone Valeria
- Pharmacy Department, S. Giovanni Bosco Hospital, 10154 Turin, Italy; (M.V.); (S.O.); (P.C.)
| | - Sara Osella
- Pharmacy Department, S. Giovanni Bosco Hospital, 10154 Turin, Italy; (M.V.); (S.O.); (P.C.)
| | - Paola Crosasso
- Pharmacy Department, S. Giovanni Bosco Hospital, 10154 Turin, Italy; (M.V.); (S.O.); (P.C.)
| | - Marika Denise Favuzzi
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Elena Rubini
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Silvia Grazietta Foddai
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Simone Baldovino
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Dario Roccatello
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| | - Daniela Rossi
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis-ERKnet Member, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, 10154 Turin, Italy; (M.R.); (I.C.); (M.D.F.); (E.R.); (S.G.F.); (S.B.); (D.R.); (D.R.)
| |
Collapse
|